WALTHAM, Mass., April 26, 2018 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its first quarter 2018 financial results will be released on Thursday, May 3, 2018 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Dial-in Number
U.S./Canada Dial-in Number: (877) 412-6083
International Dial-in Number: (702) 495-1202
Conference ID: 6978298
Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 6978298
A telephone replay will be available from approximately 11:00 a.m. ET on May 3, 2018 through midnight on May 9, 2018.
The webcast with slides will be accessible through the Investors section of the company’s website at www.amagpharma.com. A replay of the webcast will be archived on the website for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of Cbr Systems, Inc.
AMAG Pharmaceuticals Contact:
Christi Waarich
Associate Director, Investor Relations
617-498-7638


Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 



